The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.
November 30, 2020
Would people living with epilepsy benefit from palliative care?
Palliative care (PC) is an approach to the care of persons living with serious illness and their families that focuses on improving quality of life and reducing suffering by addressing complex medical symptoms, psychosocial needs, spiritual well-being, and advance care planning.
November 25, 2020
Affordability, availability and tolerability of anti-seizure medications are better predictors of adherence than beliefs: Changing paradigms from a low resource setting
Anti-seizure medication (ASM) non-adherence contributes to treatment gap and increases mortality and morbidity associated with epilepsy. Beliefs about medications are considered better predictors of ASM non-adherence than clinico-demographic factors. We aimed to look into ASM non-adherence rates among adults with epilepsy (AWE), identify the contributing barriers and determine whether medication beliefs were more powerful predictors than clinico-demographic factors.
November 23, 2020
Effects of valproate (Depakote), lamotrigine (Lamictal), and levetiracetam (Keppra) monotherapy on bone health in newly diagnosed adult patients with epilepsy
The aim of this study was to evaluate the effects of valproate (VPA), lamotrigine (LTG), and levetiracetam (LEV) on bone turnover and bone mineral density (BMD) in newly diagnosed adult patients with epilepsy…Read More